Advanced Bladder Cancer VL

Circulating Tumor DNA in Urothelial Cancer - Interview with Bishoy Faltas

Bishoy Faltas and Charles Ryan discuss some of Bishoy's work using cell-free DNA, or circulating tumor DNA, and what it means in urothelial cancer today. Circulating tumor DNA is DNA that's shed by the tumor into the bloodstream, and the advantage of the current technology and the evolving technology is that we can actually get that DNA. In this work being discussed Bishoy and colleagues are focus...

Upper Tract Urothelial Carcinoma Has a Luminal-Papillary T-cell Depleted Contexture and Activated FGFR3 Signaling - Bishoy Faltas

Alicia Morgans hosts Bishoy Faltas in a discussion about a Nature Communications publish article Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling which Bishoy was a co-author on with Brian D Robinson et al. In this study an integrated analysis of whole-exome and RNA sequencing of upper tract urothelial carcinoma (UTUC) was performed...

Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer - Matt Galsky

Professor Matt Galsky joins Alicia Morgans to share details of an analysis looking at FGFR mutations in patients who have received checkpoint inhibitor therapy on clinical trials. In this study, Matt Galsky and colleagues examined the impact of a mutated gene found in a subset of urothelial cancers on response to treatment with immunotherapy. Using data derived from two clinical trials exploring C...

Erdafitinib Treatment in Metastatic Urothelial Carcinoma - Petros Grivas

Petros Grivas and Alicia Morgans join in a conversation about the recently FDA accelerated approval of erdafitinib in metastatic bladder cancer for tumors that exhibit mutations active isoforms of FGFR 2 and FGFR 3. Dr. Grivas discusses the companion biomarkers used in the determination of genomic sequencing of the tumor tissue exhibiting FGF reception mutations. The indication for erdafitinib (pa...

Biomarker Testing in Metastatic Urothelial Carcinoma - Petros Grivas

In the rapidly evolving landscape of urothelial cancer, Alicia Morgans and Petros Grivas discuss biomarker testing in patients in urothelial cancer with an emphasis on muscle-invasive and metastatic disease. Having an effect on the day to day treatment algorithms, Petros fields questions in the metastatic setting including who are the patients we are testing and how we are using the results. Biogr...

Results from CALGB 90601 in Metastatic Urothelial Carcinoma - Jonathan Rosenberg

Jonathan Rosenberg, MD, discusses results presented of "Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Gemcitabine and Cisplatin with Bevacizumab or Placebo in Patients with Metastatic Urothelial Carcinoma — CALGB 90601" (Alliance). Dr. Rosenberg confirms that the addition of bevacizumab did not improve overall survival when added to gemcitabine and cisplatin chemotherapy a...

Novel New Approaches in the Neoadjuvant Disease Setting for Bladder Cancer - Petros Grivas

Monty Pal and Petros Grivas discuss new approaches being taken in the neoadjuvant disease setting for bladder cancer. Petros highlights the urgent unmet need for novel therapies for bladder cancer that immunotherapy is trying to meet through innovative clinical trials. He references two clinical phase II trials, the PURE-01 by Dr. Necchi and colleagues, pembrolizumab in Cisplatin-fit patients, and...

Erdafitinib in Bladder Cancer - Arjun Balar

FGFR alterations and specifically ones involving the third and the second isotype of the receptor, FGFR3 and FGFR2, are activated and present in between 15 to 20%, possibly higher, of patients with locally advanced and metastatic bladder cancer. We know that these are genetic drivers and the therapeutic targeting of this pathway can lead to responses. Patients should be selected for therapy based...

Neoadjuvant Treatment in Muscle Invasive Bladder Cancer- Andrea Necchi

Andrea Necchi and Alicia Morgans discuss the evolution of neoadjuvant treatment for muscle-invasive bladder cancer (MIBC) including the role of immunotherapy and chemotherapy prior to radical surgery. They discuss the PURE-01study which included all-comers regardless of cisplatin eligibility. The early data from PURE-01 with neoadjuvant pembrolizumab demonstrated a 42% pathological complete respon...

Joshua J. Meeks on SWOG 1806 Study

Josh Meeks reviews the SWOG 1806 study protocol with Alicia Morgans. T he SWOG 1806 study , Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer is expected to begin enrollment in May 2019. This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle...

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.